The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Open accessAbstract
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus meeting was held among the study neurologists and neuropsychologists to clinically determine each potential participant’s cognitive status grouping (NC, MCI, or dementia) based on a standardized approach used in National Institute of Health (NIH)-funded Alzheimer’s Disease Centers across the United States (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
From Internet-Based Conversational Engagement Randomized Controlled Clinical Trial (I-CONECT) Among Socially Isolated Adults 75+ Years Old With Normal Cognition or Mild Cognitive Impairment: Topline Results (2024) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the atrophy of specific brain regions shown by structural MRI is an important part of the diagnostic criteria for FTD and AD (McKhann et al., 2011; Rascovsky et al., 2011)”
From Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease (2021) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diagnosis of AD was made in accordance with the NINCDS-ADRCA criteria (McKhann et al., 2011) and MCI was diagnosed according to the Mayo criteria (Petersen et al., 1999).”
From Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction (2018) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During this extended preclinical period prior to the dementia diagnosis, many patients develop behavioral or neuropsychiatric changes, including agitation, irritability, decreased motivation, loss of empathy, and depression, which increase the risk of transition to mild cognitive impairment and AD.12-14”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“All patients (n = 96) were clinically evaluated by expert neurologists (M.G., D.J.I.) at the time of recording at the frontotemporal degeneration center (FTDC) in the neurology department of the Hospital of the University of Pennsylvania, and they were classified at a weekly consensus meeting at the FTDC using established clinical criteria.”
From Automatic classification of AD pathology in FTD phenotypes using natural speech (2024) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“AD is clinically diagnosed using the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria [5].”
From Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Probable AD diagnoses were assigned according to both NINCDS/ADRDA criteria (23), and the core clinical NIA-AA criteria (28).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [28]
In the citing paper
“The University of California San Francisco (UCSF) Memory and Aging Center Dementia cohort consisted of 152 carefully phenotyped older adults meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for either mild-cognitive impairment22 or probable dementia because of AD.23”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [23]
In the citing paper
“More recently, the imaging of amyloid with compounds such as the radiolabeled Pittsburgh compound B (11C-PiB) has received much interest and been proposed as a biomarker of AD.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“These, along with amyloid imaging using positron emission tomography (PET), may help determine AD as the main or contributory cause of the cognitive disorder.”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“CSF markers for AD are, however, better developed, with lower levels of Aβ42 and elevated levels of tau/phosphorylated-tau being indicative of AD pathology.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“The clinical criteria used most commonly are the NIA‐AA criteria for dementia 89 and mild cognitive impairment 90 due to Alzheimer's disease.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [89]
In the citing paper
“The development of the DSM-5 criteria for the various subtypes involved extensive discussions with experts from diverse fields to harmonize the DSM criteria with criteria developed by other expert groups, such as the NIA-AA, 20,27 the frontotemporal dementia expert group, 28,29 the consortium on DLB, 30 the VASCOG working group, 31 the Movement Disorder Study Task Force on Parkinson Disease 32 and”
From Classifying neurocognitive disorders: the DSM-5 approach (2014) · cites this paper as [27]
In the citing paper
“This different pattern of results in bvFTD and AD may reflect the preferential and widespread damage within the AIN in bvFTD11,14,16, 17, 18, 19, 20,24 whereas in AD, AIN damage appears to be more circumscribed.17,38,88”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“Second, patients received diagnoses based on established clinical criteria only,37,38 without testing for ATN biomarkers in AD such as the deposition of amyloid-β and tau proteins established via Positron Emission Tomography, CSF, or plasma in AD.94, 95, 96, 97”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“The diagnosis was concluded in a multidisciplinary meeting using consensus criteria for probable FTD, PPD (DSM-V), and AD [25,31,32].”
In the citing paper
“Detection of abnormal Aβ accumulation (Aβ positivity) may support the clinical diagnosis of AD1,2 and is essential for including participants in clinical AD trials targeting Aβ.3”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [2]
In the citing paper
“Diagnosis was established by the multidisciplinary teams at each research institute based on current consensus diagnostic criteria (McKhann et al., 2011; Postuma et al., 2015; Rascovsky et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“AD patients present with predominant episodic memory loss and impaired executive functioning, with atrophy observed in the medial temporal lobe, most notably in the hippocampus and posterior cingulate (McKhann et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“A diagnosis of probable AD had been made prior to the study by neurologists at the Memory Center according to the clinical criteria of the National Institute on Aging and the Alzheimer’s Association criteria for probable AD [1].”
From The effects of confinement on neuropsychiatric symptoms in Alzheimer's disease during the COVID-19 crisis (2020) · cites this paper as [1]
In the citing paper
“The 3 major clinical criteria for the AD spectrum are the revised 2011 NIA-AA criteria, 32,39 the International Working Group (Dubois and colleagues 39,40 ) 2010 revised new lexicon criteria, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.41”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for AD recognizes nonamnestic AD presentations that include language, visuospatial, and executive dysfunction features.32”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“dementia-level impairment requires cognitive or behavioral symptoms”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“MCI diagnosis is a matter of”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“With the advent of biomarkers that enable in vivo identification of underlying AD pathological conditions, and the acceptance that AD begins years before the emergence of cognitive impairment, AD is now commonly accepted as a clinicopathological entity7,8 that can be diagnosed without histopathological examination, in the presence of appropriate biomarker evidence of an underlying condition.6,8,9”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 7×
“Initial efforts to incorporate biomarkers into the diagnosis of AD dementia and MCI [14] need to be coupled with a more comprehensive approach to the diagnostic process.”
BackgroundInfluentialSelf-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Self-citationRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,401–1,500 of 1,532
Diagnóstico del deterioro cognitivo vascular y sus principales categorías
Rodríguez García, P. L., & Rodríguez García, D. (2015) · Neurología · doi:10.1016/j.nrl.2011.12.014 · Cited by 33
Using narratives in differential diagnosis of neurodegenerative syndromes
Faroqi-Shah, Y., Treanor, A., Ratner, N. B., Ficek, B., Webster, K., & Tsapkini, K. (2020) · Journal of Communication Disorders · doi:10.1016/j.jcomdis.2020.105994 · Cited by 32
Huang, W.-C., Chang, M.-C., Wang, W.-F., & Jhang, K.-M. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.798315 · Cited by 34
Teixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
Identifying bvFTD within the wide spectrum of late onset frontal lobe syndrome: a clinical approach
Krudop, W. A., Kerssens, C. J., Dols, A., Prins, N. D., Möller, C., Schouws, S., van der Flier, W. M., Scheltens, P., Sikkes, S., Stek, M. L., et al. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.04.002 · Cited by 33
Self-citationGallagher, D., Kiss, A., Lanctot, K. L., & Herrmann, N. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12331 · Cited by 34
Ding, H., Wang, B., Hamel, A. P., Melkonyan, M., Ang, T. F. A., Au, R., & Lin, H. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1271680 · Cited by 32
Falgàs, N., Ruiz‐Peris, M., Pérez‐Millan, A., Sala‐Llonch, R., Antonell, A., Balasa, M., Borrego‐Écija, S., Ramos‐Campoy, O., Augé, J. M., Castellví, M., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24925 · Cited by 32
Jiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36
Ibnidris, A., Robinson, J. N., Stubbs, M., Piumatti, G., Govia, I., & Albanese, E. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02018-y · Cited by 30
Azarpazhooh, M. R., Avan, A., Cipriano, L. E., Munoz, D. G., Erfanian, M., Amiri, A., Stranges, S., & Hachinski, V. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101002 · Cited by 32
A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease
Lutz, M. W., Sundseth, S. S., Burns, D. K., Saunders, A. M., Hayden, K. M., Burke, J. R., Welsh‐Bohmer, K. A., Roses, A. D., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.12.002 · Cited by 30
TREM2 expression in the brain and biological fluids in prion diseases
Diaz-Lucena, D., Kruse, N., Thüne, K., Schmitz, M., Villar-Piqué, A., da Cunha, J. E. G., Hermann, P., López-Pérez, Ó., Andrés-Benito, P., Ladogana, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02296-1 · Cited by 32
Leuzy, A., Zimmer, E. R., Heurling, K., Rosa-Neto, P., & Gauthier, S. (2014) · Amyloid · doi:10.3109/13506129.2014.926267 · Cited by 31
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Detecting clinical change with the CDR-FTLD: differences between FTLD and AD dementia
Mioshi, E., Flanagan, E., & Knopman, D. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4556 · Cited by 29
“Inclusion criteria for dementia due to AD (n=253) were diagnosis of possible or probable AD (McKhann et al., 2011) and no concurrent diagnosis of vascular dementia, dementia with Lewy bodies, depression or other psychiatric disease at the first visit.”
BackgroundSelf-citationJohnen, A., Reul, S., Wiendl, H., Meuth, S. G., & Duning, T. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.04.002 · Cited by 29
Association between thyroid function and Alzheimer's disease: A systematic review
Figueroa, P. B. S., Ferreira, A. F. F., Britto, L. R., Doussoulin, A. P., & Torrão, A. D. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00760-1 · Cited by 28
Mechanism of anti-dementia effects of mangiferin in a senescence accelerated mouse (SAMP8) model
Du, Z., Fanshi, F., Lai, Y.-H., Chen, J.-R., Hao, E., Deng, J., & Hsiao, C.-D. (2019) · Bioscience Reports · doi:10.1042/bsr20190488 · Cited by 30
TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer’s Disease
Pillai, J. A., Bebek, G., Khrestian, M., Bena, J., Bergmann, C. C., Bush, W. S., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638922 · Cited by 29
Novel CSF biomarkers to discriminate FTLD and its pathological subtypes
del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.629 · Cited by 30
Brunelle-Hamann, L., Thivierge, S., & Simard, M. (2015) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2014.964731 · Cited by 29
Peña-Bautista, C., Vigor, C., Galano, J.-M., Oger, C., Durand, T., Ferrer, I., Cuevas, A., López-Cuevas, R., Baquero, M., López-Nogueroles, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50837-2 · Cited by 28
Deeken, F., Häusler, A., Nordheim, J., Rapp, M., Knoll, N., & Rieckmann, N. (2018) · International Psychogeriatrics · doi:10.1017/s1041610217001387 · Cited by 30
Tucholka, A., Grau-Rivera, O., Falcon, C., Rami, L., Sánchez-Valle, R., Lladó, A., Gispert, J. D., Molinuevo, J. L., & Initiative, F. T. A. D. N. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170553 · Cited by 29
Mehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29
Fristed, E., Skirrow, C., Meszaros, M., Lenain, R., Meepegama, U., Papp, K. V., Ropacki, M., & Weston, J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac231 · Cited by 29
Bernstein, A., Rogers, K. M., Possin, K. L., Steele, N. Z. R., Ritchie, C. S., Miller, B. L., & Rankin, K. P. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05013-7 · Cited by 28
Levada, O. A., Cherednichenko, N. V., Trailin, A. V., & Troyan, A. S. (2016) · Disease Markers · doi:10.1155/2016/4095723 · Cited by 28
Bertoux, M., Flanagan, E. C., Hobbs, M., Ruiz-Tagle, A., Delgado, C., Miranda, M., Ibáñez, A., Slachevsky, A., & Hornberger, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170771 · Cited by 28
Veneziani, F., Panza, F., Solfrizzi, V., Capozzo, R., Barulli, M. R., Leo, A., Lozupone, M., Fontana, A., Arcuti, S., Copetti, M., et al. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000041 · Cited by 27
Pan, F., Huang, Y., Cai, X., Wang, Y., Guan, Y., Deng, J., Yang, D., Zhu, J., Zhao, Y., Xie, F., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00295-9 · Cited by 27
“Participants with cognitive symptoms but not met the diagnostic criteria for dementia were classi fi ed as MCI if they met the actuarial neuropsychological criteria put forward by Jak and Bondi 34 .”
Should I trust you? Learning and memory of social interactions in dementia
Wong, S., Irish, M., O’Callaghan, C., Kumfor, F., Savage, G., Hodges, J. R., Piguet, O., & Hornberger, M. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.08.016 · Cited by 28
Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls
Kolarova, M., Sengupta, U., Bartos, A., Ricny, J., & Kayed, R. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170048 · Cited by 27
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Nielsen, T. R., Phung, T. K. T., Chaaya, M., Mackinnon, A., & Waldemar, G. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000441649 · Cited by 26
Das, S., Dewit, N., Jacobs, D., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Coppens, S., Quaglia, M., Hirtz, C., Teunissen, C. E., & Vanmechelen, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137221 · Cited by 26
Looking for measures of disease severity in the frontotemporal dementia continuum
Premi, E., Gualeni, V., Costa, P., Cosseddu, M., Gasparotti, R., Padovani, A., & Borroni, B. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160178 · Cited by 26
Reus, L. M., Vijverberg, E. G., Tijms, B. M., Kate, M. T., Gossink, F., Krudop, W. A., Campo, M. D., Teunissen, C. E., Barkhof, F., van der Flier, W. M., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.014 · Cited by 26
Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review
Rostamzadeh, A., Kahlert, A., Kalthegener, F., & Jessen, F. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00956-8 · Cited by 26
Wang, Z., Dai, Z., Shu, H., Liu, D., Guo, Q., He, Y., & Zhang, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160724 · Cited by 26
Malone, C., Deason, R. G., Palumbo, R., Heyworth, N., Tat, M., & Budson, A. E. (2019) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2018.1513453 · Cited by 26
In vivo [ 18 F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease
Day, G. S., Gordon, B. A., Perrin, R. J., Cairns, N. J., Beaumont, H., Schwetye, K., Ferguson, C., Sinha, N., Bucelli, R., Musiek, E. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005064 · Cited by 26
Self-citationCerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
In vivo exploration of synaptic projections in frontotemporal dementia
Salmon, E., Bahri, M. A., Plenevaux, A., Becker, G., Seret, A., Delhaye, E., Degueldre, C., Balteau, E., Lemaire, C., Luxen, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95499-1 · Cited by 21
Soucy, J.-P., Bartha, R., Bocti, C., Borrie, M., Burhan, A. M., Laforce, R., & Rosa-Neto, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt199 · Cited by 25
Can the DSM-5 framework enhance the diagnosis of MCI?
Ganguli, M. (2013) · Neurology · doi:10.1212/01.wnl.0000436944.01023.e5 · Cited by 26
Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer’s Disease
Bartos, A., Fialová, L., & Švarcová, J. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180039 · Cited by 25
Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification
Zhong, H., Zhou, X., Uhm, H., Jiang, Y., Cao, H., Chen, Y., Mak, T. T. W., Lo, R. M. N., Wong, B. W. Y., Cheng, E. Y. L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13691 · Cited by 25
Dols, A., van Liempt, S., Gossink, F., Krudop, W. A., Sikkes, S., Pijnenburg, Y. A. L., & Stek, M. L. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09844 · Cited by 25
Newton, P., the BIOCARD Research Team, Tchounguen, J., Pettigrew, C., Lim, C., Lin, Z., Lu, H., Moghekar, A., Albert, M., & Soldan, A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220846 · Cited by 23
Impact of diagnosed (vs undiagnosed) dementia on family caregiving experiences
Burgdorf, J. G., & Amjad, H. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18155 · Cited by 24
Miller, S. R., Luxem, K., Lauderdale, K., Nambiar, P., Honma, P. S., Ly, K. K., Bangera, S., Bullock, M., Shin, J., Kaliss, N., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114870 · Cited by 24
“10,11 12-14 Thus, these behavioral changes may be the earliest symptoms of preclinical stages of AD.”
Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
Qin, W., Li, F., Jia, L., Wang, Q., Li, Y., Wei, Y., Li, Y., Jin, H., & Jia, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.900773 · Cited by 23
Talk2Me: Automated linguistic data collection for personal assessment
Komeili, M., Pou-Prom, C., Liaqat, D., Fraser, K. C., Yancheva, M., & Rudzicz, F. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212342 · Cited by 23
Montesanto, A., Crocco, P., Anfossi, M., Smirne, N., Puccio, G., Colao, R., Maletta, R., Passarino, G., Bruni, A. C., & Rose, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150993 · Cited by 24
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22
Goncalves, A., & Antonetti, D. A. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00386-0 · Cited by 22
Gilmore-Bykovskyi, A. L., Block, L. M., Walljasper, L., Hill, N., Gleason, C., & Shah, M. N. (2018) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocy070 · Cited by 21
Scrascia, F., Curcio, G., Ursini, F., Trotta, L., Quintiliani, L., Migliore, S., Altamura, C., Pitocco, F., Altavilla, R., Melgari, J.-M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130788 · Cited by 22
Zhutovsky, P., Vijverberg, E. G. B., Bruin, W. B., Thomas, R. M., Wattjes, M. P., Pijnenburg, Y. A. L., van Wingen, G. A., & Dols, A. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181004 · Cited by 20
Gould, R. L., Thompson, B. J., Rawlinson, C., Kumar, P., White, D., Serfaty, M. A., Graham, C. D., McCracken, L. M., Bursnall, M., Bradburn, M., et al. (2022) · BMC Neurology · doi:10.1186/s12883-022-02950-5 · Cited by 16
Pelka, O., Friedrich, C. M., Nensa, F., Mönninghoff, C., Bloch, L., Jöckel, K.-H., Schramm, S., Sanchez Hoffmann, S., Winkler, A., Weimar, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236868 · Cited by 22
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
Gao, L., Chen, J., Gu, L., Shu, H., Wang, Z., Liu, D., Yan, Y., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00256 · Cited by 21
Alzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Patients are often diagnosed in this stage (40); and (c) Clinical AD: thought, behavior and memory symptoms that impair daily activity and life (41).”
BackgroundA microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
Midorikawa, A., Leyton, C. E., Foxe, D., Landin-Romero, R., Hodges, J. R., & Piguet, O. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160440 · Cited by 20
Teipel, S. J., Dyrba, M., Ballarini, T., Brosseron, F., Bruno, D., Buerger, K., Cosma, N.-C., Dechent, P., Dobisch, L., Düzel, E., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215196 · Cited by 20
Intermittent Fasting: A Promising Approach for Preventing Vascular Dementia
Yoon, G., & Song, J. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.1 · Cited by 20
Cha, W.-J., Yi, D., Ahn, H., Byun, M. S., Chang, Y. Y., Choi, J.-M., Kim, K., Choi, H., Jung, G., Kang, K. M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01417-8 · Cited by 20
Kunkle, B. W., Carney, R. M., Kohli, M. A., Naj, A. C., Hamilton-Nelson, K. L., Whitehead, P. L., Wang, L., Lang, R., Cuccaro, M. L., Vance, J. M., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.014 · Cited by 19
Lima-Silva, T. B., Mioshi, E., Bahia, V. S., Cecchini, M. A., Cassimiro, L., Guimarães, H. C., Gambogi, L. B., Caramelli, P., Balthazar, M., Damasceno, B., et al. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720944239 · Cited by 18
Hazelton, J. L., Carneiro, F., Maito, M., Richter, F., Legaz, A., Altschuler, F., Cubillos-Pinilla, L., Chen, Y., Doherty, C. P., Baez, S., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.10.013 · Cited by 21
Niemantsverdriet, E., Feyen, B. F. E., Le Bastard, N., Martin, J.-J., Goeman, J., De Deyn, P. P., Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170927 · Cited by 19
Naudin, M., Mondon, K., El-Hage, W., Perriot, E., Boudjarane, M., Desmidt, T., Lorette, A., Belzung, C., Hommet, C., & Atanasova, B. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.03.021 · Cited by 19
Distinct tau PET imaging patterns in typical and atypical Alzheimer’s disease
Sarazin, M., Lagarde, J., & Bottlaender, M. (2016) · Brain · doi:10.1093/brain/aww041 · Cited by 20
Lima-Silva, T. B., Bahia, V. S., Carvalho, V. A., Guimarães, H. C., Caramelli, P., Balthazar, M., Damasceno, B., Bottino, C. M. D. C., Brucki, S. M. D., Mioshi, E., et al. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn74000006 · Cited by 19
Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease
Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Lirng, J.-F., Wang, S.-J., & Fuh, J.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05390-1 · Cited by 18
The Effect of Baseline Patient and Caregiver Mindfulness on Dementia Outcomes
Innis, A. D., Tolea, M. I., & Galvin, J. E. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201292 · Cited by 18
Ramos de Matos, M., Ferreira, C., Herukka, S.-K., Soininen, H., Janeiro, A., Santana, I., Baldeiras, I., Almeida, M. R., Lleó, A., Dols-Icardo, O., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180512 · Cited by 18
Apathy and disinhibition related to neuropathology in amnestic versus behavioral dementias
Borges, L. G., Rademaker, A. W., Bigio, E. H., Mesulam, M.-M., & Weintraub, S. (2019) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317519853466 · Cited by 16
Self-citationOlfactory bulb integrity in frontotemporal dementia and Alzheimer’s disease
Carnemolla, S. E., Kumfor, F., Liang, C. T., Foxe, D., Ahmed, R. M., & Piguet, O. (2022) · Journal of Alzheimer’s Disease · doi:10.3233/jad-220080 · Cited by 16
Identifying progression-specific Alzheimer’s subtypes using multimodal transformer
Machado Reyes, D., Chao, H., Hahn, J., Shen, L., Yan, P., & Initiative, F. T. A. D. N. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040421 · Cited by 17
An, X., He, J., Bi, B., Wu, G., Xu, J., Yu, W., & Ren, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1510729 · Cited by 16
Diagnostic Instability Over Time in the Late-Onset Frontal Lobe Syndrome: When Can We Say it's FTD?
de Boer, S. C. M., Gossink, F., Krudop, W., Vijverberg, E., Schouws, S., Reus, L. M., Pijnenburg, Y. A. L., & Dols, A. (2023) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.02.006 · Cited by 15
Souchet, B., Michaïl, A., Heuillet, M., Dupuy-Gayral, A., Haudebourg, E., Pech, C., Berthemy, A., Autelitano, F., Billoir, B., Domoto-Reilly, K., et al. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.34 · Cited by 15
Schjønning Nielsen, M., Simonsen, A. H., Siersma, V., Engedal, K., Jelic, V., Andersen, B. B., Naik, M., Hasselbalch, S. G., & Høgh, P. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000490788 · Cited by 15
Beauchet, O., Launay, C. P., Chabot, J., Levinoff, E. J., & Allali, G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160604 · Cited by 15
APOE-ε4-related differences in left thalamic microstructure in cognitively healthy adults
Mole, J. P., Fasano, F., Evans, J., Sims, R., Kidd, E., Aggleton, J. P., & Metzler-Baddeley, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-75992-9 · Cited by 15
Gildengers, A. G., Butters, M. A., Albert, S. M., Anderson, S. J., Dew, M. A., Erickson, K., Garand, L., Karp, J. F., Lockovich, M. H., Morse, J., et al. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.10.010 · Cited by 15
Mindfulness and Care Experience in Family Caregivers of Persons Living with Dementia
Tolea, M. I., Camacho, S., Cohen, I. R., & Galvin, J. E. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220069 · Cited by 17
“Patients and research participants were categorized as either cognitively normal, MCI (prodromal stage), or dementia using standard criteria for AD [47], dementia with Lewy bodies (DLB) [48], vascular contributions to cognitive impairment and dementia (VCID) [49], and frontotemporal degeneration (FTD) [50].”
Yang, B., Yu, H., Xing, M., He, R., Liang, R., & Zhou, L. (2017) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2017.05.003 · Cited by 14
Chen, P., Hsu, H., Chao, Y., Nouchi, R., Wang, P., & Cheng, C. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13691 · Cited by 14
Bae, J., Logan, P. E., Acri, D. J., Bharthur, A., Nho, K., Saykin, A. J., Risacher, S. L., Nudelman, K., Polsinelli, A. J., Pentchev, V., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13319 · Cited by 14
Hazelton, J. L., Della Bella, G., Barttfeld, P., Dottori, M., Gonzalez-Gomez, R., Migeot, J., Moguilner, S., Legaz, A., Hernandez, H., Prado, P., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105614 · Cited by 14
Suhonen, N.-M., Hallikainen, I., Hänninen, T., Jokelainen, J., Krüger, J., Hall, A., Pikkarainen, M., Soininen, H., & Remes, A. M. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160983 · Cited by 14
Automatic classification of AD pathology in FTD phenotypes using natural speech
Cho, S., Olm, C. A., Ash, S., Shellikeri, S., Agmon, G., Cousins, K. A. Q., Irwin, D. J., Grossman, M., Liberman, M., & Nevler, N. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13748 · Cited by 13
Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease
Huang, Y.-L., Tsai, T.-H., Shen, Z.-Q., Chan, Y.-H., Tu, C.-W., Tung, C.-Y., Wang, P.-N., & Tsai, T.-F. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01651-0 · Cited by 13
Theoretical impact of the AT(N) framework on dementia using a community autopsy sample
Burke, B. T., Latimer, C., Keene, C. D., Sonnen, J. A., McCormick, W., Bowen, J. D., McCurry, S. M., Larson, E. B., & Crane, P. K. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12348 · Cited by 13
Metadata
- Authors
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H.
- Affiliations
- Johns Hopkins University (US)
- Mayo Clinic (US)
- Lady Davis Institute for Medical Research (CA)
- Harvard University (US)
- University of California, Irvine (US)
- University of Pittsburgh (US)
- National Institute of Neurological Disorders and Stroke (US)
- Columbia University Irving Medical Center (US)
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- UCL Queen Square Institute of Neurology (GB)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- Department of Psychiatry Northwestern Feinberg School of Medicine Chicago IL USA
- National Institutes of Health (US)
- Corresponding author
- McKhann, Guy M.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 263-269
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3312024
- OpenAlex
- W2115017507
- Semantic Scholar
- 37d2d04f8c09da1f0cf8434a38a51841b5b703bf
- Cited by
- 18,657
- References
- 44
- Citations by year
- 2026: 893 · 2025: 1313 · 2024: 1585 · 2023: 1543 · 2022: 1670 · 2021: 1796 · 2020: 1602 · 2019: 1448 · 2018: 1297 · 2017: 1200 · 2016: 1088 · 2015: 1062 · 2014: 794 · 2013: 715 · 2012: 491
- FWCI
- 471.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute on Aging
- Forest Pharmaceuticals
- Alzheimer's Association
- Fidelity Biosciences
- Baxter International
- Pfizer
- Johnson and Johnson
- Avid Radiopharmaceuticals
- GE Healthcare
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, dementia diagnosis
- MeSH terms
- Alzheimer Disease, Diagnosis, Differential, Diagnostic Imaging, Humans, Societies, Medical, United States, Biomarkers, Practice Guidelines as Topic, Disease Progression, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
